Cargando…
Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent For Coronary Artery Disease
BACKGROUND: Despite great reduction of in-stent restenosis, first-generation drug-eluting stents (DESs) have increased the risk of late stent thrombosis due to delayed endothelialization. Arsenic trioxide, a natural substance that could inhibit cell proliferation and induce cell apoptosis, seems to...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833980/ https://www.ncbi.nlm.nih.gov/pubmed/25758270 http://dx.doi.org/10.4103/0366-6999.152490 |
_version_ | 1782427423474712576 |
---|---|
author | Shen, Li Yang, Wei Yin, Jia-Sheng Liu, Xue-Bo Wu, Yi-Zhe Sun, Ai-Jun Qian, Ju-Ying Ge, Jun-Bo |
author_facet | Shen, Li Yang, Wei Yin, Jia-Sheng Liu, Xue-Bo Wu, Yi-Zhe Sun, Ai-Jun Qian, Ju-Ying Ge, Jun-Bo |
author_sort | Shen, Li |
collection | PubMed |
description | BACKGROUND: Despite great reduction of in-stent restenosis, first-generation drug-eluting stents (DESs) have increased the risk of late stent thrombosis due to delayed endothelialization. Arsenic trioxide, a natural substance that could inhibit cell proliferation and induce cell apoptosis, seems to be a promising surrogate of sirolimus to improve DES performance. This randomized controlled trial was to evaluate the efficacy and safety of a novel arsenic trioxide-eluting stent (AES), compared with traditional sirolimus-eluting stent (SES). METHODS: Patients with symptoms of angina pectoris were enrolled and randomized to AES or SES group. The primary endpoint was target vessel failure (TVF), and the second endpoint includes rates of all-cause death, cardiac death or myocardial infarction, target lesion revascularization (TLR) by telephone visit and late luminal loss (LLL) at 9-month by angiographic follow-up. RESULTS: From July 2007 to 2009, 212 patients were enrolled and randomized 1:1 to receive either AES or SES. At 2 years of follow-up, TVF rate was similar between AES and SES group (6.67% vs. 5.83%, P = 0.980). Frequency of all-cause death was significantly lower in AES group (0 vs. 4.85%, P = 0.028). There was no significant difference between AES and SES in frequency of TLR and in-stent restenosis, but greater in-stent LLL was observed for AES group (0.29 ± 0.52 mm vs. 0.10 ± 0.25 mm, P = 0.008). CONCLUSIONS: After 2 years of follow-up, AES demonstrated comparable efficacy and safety to SES for the treatment of de novo coronary artery lesions. |
format | Online Article Text |
id | pubmed-4833980 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-48339802016-04-29 Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent For Coronary Artery Disease Shen, Li Yang, Wei Yin, Jia-Sheng Liu, Xue-Bo Wu, Yi-Zhe Sun, Ai-Jun Qian, Ju-Ying Ge, Jun-Bo Chin Med J (Engl) Original Article BACKGROUND: Despite great reduction of in-stent restenosis, first-generation drug-eluting stents (DESs) have increased the risk of late stent thrombosis due to delayed endothelialization. Arsenic trioxide, a natural substance that could inhibit cell proliferation and induce cell apoptosis, seems to be a promising surrogate of sirolimus to improve DES performance. This randomized controlled trial was to evaluate the efficacy and safety of a novel arsenic trioxide-eluting stent (AES), compared with traditional sirolimus-eluting stent (SES). METHODS: Patients with symptoms of angina pectoris were enrolled and randomized to AES or SES group. The primary endpoint was target vessel failure (TVF), and the second endpoint includes rates of all-cause death, cardiac death or myocardial infarction, target lesion revascularization (TLR) by telephone visit and late luminal loss (LLL) at 9-month by angiographic follow-up. RESULTS: From July 2007 to 2009, 212 patients were enrolled and randomized 1:1 to receive either AES or SES. At 2 years of follow-up, TVF rate was similar between AES and SES group (6.67% vs. 5.83%, P = 0.980). Frequency of all-cause death was significantly lower in AES group (0 vs. 4.85%, P = 0.028). There was no significant difference between AES and SES in frequency of TLR and in-stent restenosis, but greater in-stent LLL was observed for AES group (0.29 ± 0.52 mm vs. 0.10 ± 0.25 mm, P = 0.008). CONCLUSIONS: After 2 years of follow-up, AES demonstrated comparable efficacy and safety to SES for the treatment of de novo coronary artery lesions. Medknow Publications & Media Pvt Ltd 2015-03-20 /pmc/articles/PMC4833980/ /pubmed/25758270 http://dx.doi.org/10.4103/0366-6999.152490 Text en Copyright: © 2015 Chinese Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Shen, Li Yang, Wei Yin, Jia-Sheng Liu, Xue-Bo Wu, Yi-Zhe Sun, Ai-Jun Qian, Ju-Ying Ge, Jun-Bo Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent For Coronary Artery Disease |
title | Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent For Coronary Artery Disease |
title_full | Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent For Coronary Artery Disease |
title_fullStr | Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent For Coronary Artery Disease |
title_full_unstemmed | Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent For Coronary Artery Disease |
title_short | Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent For Coronary Artery Disease |
title_sort | nine-month angiographic and two-year clinical follow-up of novel biodegradable-polymer arsenic trioxide-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833980/ https://www.ncbi.nlm.nih.gov/pubmed/25758270 http://dx.doi.org/10.4103/0366-6999.152490 |
work_keys_str_mv | AT shenli ninemonthangiographicandtwoyearclinicalfollowupofnovelbiodegradablepolymerarsenictrioxideelutingstentversusdurablepolymersirolimuselutingstentforcoronaryarterydisease AT yangwei ninemonthangiographicandtwoyearclinicalfollowupofnovelbiodegradablepolymerarsenictrioxideelutingstentversusdurablepolymersirolimuselutingstentforcoronaryarterydisease AT yinjiasheng ninemonthangiographicandtwoyearclinicalfollowupofnovelbiodegradablepolymerarsenictrioxideelutingstentversusdurablepolymersirolimuselutingstentforcoronaryarterydisease AT liuxuebo ninemonthangiographicandtwoyearclinicalfollowupofnovelbiodegradablepolymerarsenictrioxideelutingstentversusdurablepolymersirolimuselutingstentforcoronaryarterydisease AT wuyizhe ninemonthangiographicandtwoyearclinicalfollowupofnovelbiodegradablepolymerarsenictrioxideelutingstentversusdurablepolymersirolimuselutingstentforcoronaryarterydisease AT sunaijun ninemonthangiographicandtwoyearclinicalfollowupofnovelbiodegradablepolymerarsenictrioxideelutingstentversusdurablepolymersirolimuselutingstentforcoronaryarterydisease AT qianjuying ninemonthangiographicandtwoyearclinicalfollowupofnovelbiodegradablepolymerarsenictrioxideelutingstentversusdurablepolymersirolimuselutingstentforcoronaryarterydisease AT gejunbo ninemonthangiographicandtwoyearclinicalfollowupofnovelbiodegradablepolymerarsenictrioxideelutingstentversusdurablepolymersirolimuselutingstentforcoronaryarterydisease |